# Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

> **NCT05205330** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rottapharm Biotech** · enrollment: 107 (estimated)

## Conditions studied

- Refractory Metastatic Colorectal Cancer
- Solid Tumor
- Metastatic Microsatellite-stable Colorectal Cancer
- Mismatch Repair Protein Proficient
- Metastatic GI Cancers
- Gastric Cancer

## Interventions

- **DRUG:** CR6086
- **BIOLOGICAL:** AGEN2034

## Key facts

- **NCT ID:** NCT05205330
- **Lead sponsor:** Rottapharm Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-23
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205330, "Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05205330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*